CD133抗原在白血病及MDS骨髓细胞中的表达

为了探讨CD133抗原与白血病和骨髓增生异常综合症(MDS)发病的关系,采用免疫细胞化学方法检测CD133抗原在白血病和MDS中的表达。结果显示,43例急性白血病患者CD133表达的阳性率为51.2%,急性髓系白血病(AML)组(16/29,55.2%)CD133的表达与对照组(2/15,13.3%)间的差别有统计学意义(P<0.05),慢性髓系白血病(CML)的CD133表达阳性率(2/6)与对照组间的差别无统计学意义(P>0.05)。9例MDS患者中有5例呈CD133表达阳性,阳性率为55.6%,与对照组相比无显著差异(P>0.05)。在所有白血病患者中CD34 患者的CD133表达率高于CD34-患者,且差异有统计学意义(P<0.05)。CD133表达与性别、年龄、骨髓白血病细胞比例、外周血原幼细胞比例、外周血白细胞数、血红蛋白、血小板数及乳酸脱氢酶水平无显著相关性。结论:AML患者骨髓细胞CD133表达高于正常对照,CD133表达与CD34表达有相关性。CD133高表达可能是急性白血病不良预后的一个因素。

Expression of CD133 in Bone Marrow Cells of Patients with Leukemia and Myelodysplastic Syndrome

To explore the relationship between the expression of CD133 and pathogenesis of leukemia and MDS,immunocytochemistry method was used to examine the expression of CD133 in bone marrow cells of patients with leukemia and MDS.The results showed that the positive rate of CD133 in 41 acute leukemia patients was 51.2%.The expression of CD133 in AML patients(16/29,55.2%)was significantly higher than that in control group(2/15,13.3%).There was no significant difference in CD133 expression between CML and control group.The positive rate of CD133 in 9 patients with MDS was 55.56%(5/9).There was no significant difference between MDS and normal control.The expression of CD133 in all leukemia cells with CD34 was higher than that in leukemia cells with CD34-,and there was significant difference in expression of CD133 between them(P<0.05).The expression of CD133 had no relationship with the clinical prognostic factors such as sex,age,the percentage of leukemic cells in peripheral blood and in bone marrow,WBC counts,hemoglobin concentration,platelet counts and LDH level.It is concluded that the expression of CD133 in bone marrow cells of patients with AML is higher than that in control group.The expression of CD133 is significantly correlated with the expression of CD34.The high expression of CD133 may be an adverse prognostic factor in acute leukemia.